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Background
Metabolic diseases are frequently observed in HIV-infected persons and, as the risk of contracting
these diseases is age-related, their prevalence will increase in the future as a consequence of the
benefits of antiretroviral therapy (ART).
Summary of guidelines
All HIV-infected persons should be screened at regular intervals for a history of metabolic disease,
dyslipidaemia, diabetes mellitus, hypertension and alteration of body composition; cardiovascular
risk and renal function should also be assessed. Efforts to prevent cardiovascular disease will vary in
intensity depending on an individual’s absolute risk of ischaemic heart disease and should be
comprehensive in nature. Lifestyle interventions should focus on counselling to stop smoking,
modify diet and take regular exercise. A healthy diet, exercise and maintaining normal body weight
tend to reduce dyslipidaemia; if not effective, a change of ART should be considered, followed by
use of lipid-lowering medication in high-risk patients. A pre-emptive switch from thymidine
analogues is recommended to reduce the risk of development or progression of lipoatrophy. Intra-
abdominal fat accumulation is best managed by exercise and diet. Prevention and management of
type 2 diabetes mellitus and hypertension follow guidelines used in the general population. When
using medical interventions to prevent and/or treat metabolic disease(s), impairment of the efficacy
of ART should be avoided by considering the possibility of pharmacokinetic interactions and
compromised adherence. Specialists in HIV and specialists in metabolic diseases should consult each
other, in particular in difficult-to-treat cases.
Conclusion
Multiple and relatively simple approaches exist to prevent metabolic diseases in HIV-infected
persons; priority should be given to patients at high risk of contracting these diseases.
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Introduction
Prevention and management of metabolic diseases have
emerged as major challenges to physicians responsible for
the care of HIV-infected persons [1,2]. The prevalence of
metabolic diseases has increased in the last decade in
conjunction with the introduction of combination anti-
retroviral therapy (ART) [1–4], and will continue to
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increase in the next several years as the beneficial effects of
ART allow the treated population to age.
In HIV infection, uncontrolled replication of HIV, co-
infections [e.g. with hepatitis C virus (HCV)] and ART
contribute to metabolic diseases [1,2]. The prevention and
management of metabolic diseases in HIV should take all
these factors into consideration.
Healthcare professionals involved in the care of HIV-
infected persons who are not familiar with the use of ART
should consult HIV specialists before introducing or
modifying any type of treatment that HIV-infected patients
receive. Conversely, many HIV physicians are not specia-
lists in metabolic diseases, and should seek proper
consultation prior to engaging in the prevention and
management of such conditions. Situations in which
consultation is generally recommended are indicated where
appropriate in these guidelines.
Preventing or managing metabolic diseases in HIV often
involve polypharmacy, which increases the risk of sub-
optimal adherence and hence may compromise the
continued benefit of ART. Additionally, the possibility of
drug–drug interactions with ART should be carefully
considered prior to introducing any treatment. Several
websites exist for this purpose, for example www.hiv-
druginteractions.org, www.hivpharmacology.com and
www.aidsinfo.nih.gov.
There is a limited amount of evidence from randomized
controlled trials on how to most effectively manage
metabolic diseases in HIV. As a result, management is
currently mainly extrapolated from general medical guide-
lines. Based on future clinical research findings, these
guidelines will be regularly updated, at www.eacs.eu. The
guidelines posted on the Web, as well as updated versions,
will contain more detailed information and links to any
other relevant websites.
The current guidelines highlight metabolic diseases,
which are seen frequently in the routine care of HIV-
infected persons and those for whom specific issues related
to HIV infection should be considered. Other related
conditions in the management of HIV disease that are not
or not extensively discussed, but may be included in future
versions, are the following.
 Renal impairment. Both factors related to HIV and
certain antiretroviral drugs may impair renal function
[5]. Various drugs used in HIV care may need dose
adjustment in the case of impaired renal function.
 The contribution of HIV as well as ART to bone disease,
which may include loss of bone mineral content and
aseptic necrosis of the femoral head, remains unclear.
For the moment, these pathologies should be managed
as in the general population.
 Sexual dysfunction is frequently encountered and its
management often requires a multidisciplinary ap-
proach that may include both expert psychological
counselling and medical interventions.
Summary of guidelines
Screening for metabolic diseases in patients with HIV
infection
All HIV-infected persons should be screened for a history
of metabolic disease, dyslipidaemia, diabetes mellitus,
hypertension and alteration of body composition at regular
intervals. The composite of cardiovascular risk factors for
individual patients should be summarized by the calcula-
tion of the 10-year absolute risk of contracting ischaemic
heart disease (IHD). Renal function and tubular damage
should also be assessed (Table 1).
Prevention of cardiovascular disease
The intensity of efforts to prevent cardiovascular disease
depends on the absolute risk of IHD, which is calculated
using the Framingham equation [6] (see www.cphiv.dk/
tools.aspx) (Fig. 1), and possible history of cardiovascular
disease, type 2 diabetes mellitus or type 1 diabetes mellitus
with microalbuminuria. Based on this, the population can
be stratified into three risk categories: low risk (o10% 10-
year risk of IHD), medium risk (10–20% 10-year risk of IHD)
and high risk (420% 10-year risk of IHD). The preventive
efforts are diverse in nature [7,8] and require the
involvement of cardiologists, in particular if the risk of
IHD is high. Lifestyle interventions – in particular smoking
cessation [8] – should be prioritized (Table 2; see below).
Additional interventions should be based on low-density
lipoprotein (LDL)-cholesterol levels; threshold values are
indicated for each risk category in Fig. 1. For patients with
higher-than-stipulated LDL-cholesterol threshold values,
modification of ART should be considered, provided that
one or more drugs used as part of the therapy is believed to
contribute to LDL-cholesterol increases, and if substitution
of this (these) drug(s) by other drugs will not compromise
the antiviral efficacy. Figure 2 indicates a rough stratifica-
tion of the metabolic impact of various antiretroviral drugs.
If the LDL-cholesterol levels still remain above threshold
values, consideration should be given to the initiation of
lipid-lowering medication (Tables 3 and 4; see below).
Additional recommended medical interventions to pre-
vent cardiovascular disease are as follows.
 Treat hypertension (see Table 10 below).
 Provide low-dose acetylsalicylic acid: only indicated in
high-risk patients (right column in Fig. 1) as risk of
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intracerebral bleeding is increased by 25% and extra-
cerebral bleeding by 50%; harm probably exceeds
benefit if risk of IHD is lower.
The projected benefits of these interventions are as follows:
per 10mmHg reduction of systolic blood pressure, per
1mmol/L (39mg/dL) reduction in total cholesterol and
with use of low-dose acetylsalicylic acid, each reduces risk
of IHD by 20–25%. These benefits are additive [9]. Smoking
cessation reduces risk of IHD the most – by 50% – and this
is also additive to the other interventions. Hence, by
combining the various interventions in patients in whom
they are all indicated, the absolute risk can be reduced by
more than 80%.
Lifestyle interventions
Cessation of smoking reduces the risk of contracting
cardiovascular and malignant diseases, and should be
prioritized in all patients (Table 2). If not successful on the
first attempt, patients should be referred to a specialized
stop smoking clinic [10]. Diet counselling may reduce
dyslipidaemia and risk of obesity and should focus on
reducing the intake of fat and cholesterol and increasing
the intake of vegetables and fibre-containing food.
Table 1 Screening for metabolic disease in patients with HIV
Assessment Patient’s condition Frequency of assessment
History Family history for premature IHD,z diabetes,
hypertension
Concomitant therapy against
dyslipidaemia/hypertension/diabetes
Concomitant therapy with risk for diabetes/
dyslipidaemia
Current lifestyle (alcohol use, smoking,
aerobic exercise)
Every patient
At HIV-diagnosis
At HIV-diagnosis, before start of ART, and
annually thereafter unless specifically
indicated*
Lipids Fastingw TC
Fastingw TG
Fastingw LDL-c1HDL-c
Every patient
At HIV-diagnosis, before start of ART, and
annually thereafter unless specifically
indicated*
Glucosez Fastingw glucose Every patient At HIV-diagnosis, before start of ART, and
annually thereafter unless specifically
indicated*
Body composition Body mass index
Waist circumference
Waist-to-hip ratio
Clinical lipodystrophy assessment
Every patient At HIV-diagnosis, before start of ART,
annually thereafter
Hypertension Blood pressure Every patient At HIV-diagnosis, before ART, annually
thereafter unless specifically indicated*
Cardiovascular disease Risk assessment§
ECG
Every patient without IHD
(Men440 years; women450)
Before ART, and annually thereafter
Annually
Renal failure Estimated glomerular filtration rate** Patients receiving drugs cleared via
the kidneys
Before initiation of drug in question, after 4
weeks, 6 months, and if remaining normal
then once annually
zCardiovascular events in a first degree male relative o55 years or in a first degree female relative o65 years.
*Assessment and monitoring should increase in frequency in cases of severe dyslipidaemia (see Table 4), elevated blood pressure (see Table 10) or elevated
fasting blood glucose levels (see Table 6) and/or if medical interventions are instituted to correct these conditions.
wFasting defined as a time period without caloric intake of at least 8 h.
zOral glucose tolerance test may be considered if repeated fasting glucose levels are in the range of 6.1–6.9mmol/L (110–125mg/dL) as it may reveal
the presence of diabetes in such patients.
§Use risk calculators for estimating 10-year risk of developing IHD events – www.cphiv.dk/tools.aspx. Of note, if individual patients receive medication to
control dyslipidaemia and/or hypertension, interpretation of the estimation should be done with caution.
**Use calculator to estimate glomerular filtration rate (eGFR) according to Cockcroft–Gault – www.cphiv.dk/tools.aspx.
HDL-c, HDL-cholesterol; IHD, ischaemic heart disease; LDL-c, LDL-cholesterol; TC, total cholesterol; TG, triglycerides.
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  LDL-c cut-off levels [units: mmol/L (mg/dL)] are higher than in guidelines for the general population (more stringent levels where some experts would 
consider intervention also indicated in parentheses below). In cases where LDL-c cannot be reliably calculated because of high triglyceride levels, the 
non-HDL-c target level should be used which is 0.8 mmol/L (30 mg/dL) higher than the corresponding LDL-c target. 
 Options for ART modification include: (1) replacing PI(/r) by NNRTI, or by another PI(/r) known to cause less metabolic disturbance (see Fig. 2); (2)
replacing d4T or ZDV by TDF. In patients with >20% 10-year risk or with prior CVD, the risk of CVD events and cardiac death will usually be higher than 
risk of progression to AIDS or death and in such patients, a strategy to reduce risk of CVD by switching ART is hence most appr
* Use Framingham equation (see www.cphiv.dk/tools.aspx).
opriate.  
Estimate risk of IHD in next 10 years*
IHD >20%, prior CVD, type II diabetes, 
type I diabetes with microalbuminuria
IHD risk 10–20%IHD risk < 10%
Consider modifying ART, if: 
(i) LDL-c is above cut-off, (ii) ART thought to 
contribute to ↑ LDL-c level, (iii) if possible without 
compromising HIV suppression
Consider modifying ART, if: 
(i) LDL-c is above cut-off, (ii) ART thought to 
contribute to ↑ LDL-c level, (iii) if possible without 
compromising HIV suppression
Strongly consider modifying ART, if: 
(ii) LDL-c is above cut-off, (ii) ART thought to 
contribute to ↑ LDL-c level, (iii) if possible without 
compromising HIV suppression
LDL-c cut-off level: 5 mmol/L  
(∼190 mg/dL)  
[5–4 mmol/L (∼190 – ∼155 mg/dL)]
LDL-c cut-off level: 4 mmol/L 
(∼155 mg/dL) 
[4–3 mmol/L (∼155 – ∼115 mg/dL)]
If lifestyle changes, with or without modification of ART, do not result in sufficient lowering of LDL-c to below target level,  use of lipid-lowering medication 
should be considered (see Table 4).  
Encourage lifestyle changes (diet, exercise, cessation of smoking), reduce visceral fat, reduce insulin resistance and treat hypertension 
LDL-c cut-off level: 3 mmol/L 
(∼115 mg/dL) 
[3–2 mmol/L (∼115 – ∼80 mg/dL)]
Fig. 1 Prevention of cardiovascular disease. ABC, abacavir; ART, antiretroviral therapy; CVD, cardiovascular disease; d4T, stavudine; HDL-c, high-
density lipoprotein cholesterol; IHD, ischaemic heart disease; LDL-c, low-density lipoprotein cholesterol; NNRTI, nonnucleoside reverse
transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI/r, protease inhibitor boosted with ritonavir; TDF, tenofovir DF; ZDV,
zidovudine.
Table 2 Lifestyle interventions*
Intervention Principles
Stop smoking
counselling
Brief unambiguous statement about need to stop smoking
If patient is not contemplating, try to motivate and emphasize positive short-term aspects (more money for better things, better taste for food,
better skin, less dyspnoea), and long-term benefits (prevention of COPD, IHD, stroke, lung cancer)
If patient is contemplating, try to fix stop date, establish reward system
Use nicotine substitution (patch, chewing gum, spray), varenicline, or bupropion (note: bupropion may interact with PI and NNRTI) during
weaning phase if necessary
Consider referring patient to specialized stop smoking clinics
Anticipate relapses, explain and consider them as part of the weaning process to final nicotine abstinence
Diet counselling Limit intake of saturated fat and cholesterol
Reduce total fat intake to o30% and dietary cholesterol to o300mg/day
Emphasize intake of vegetables, fruits, grain products with fibre
Emphasize consumption of fish, poultry (without skin), lean meat and low fat dietary intake
Keep caloric intake balanced with energy expenditure
Consider referral to dietician, 1 week food and drink diary to discover ‘hidden’ calories
Avoid binge eating (‘yo-yo dieting’)
In patients with HIV-related wasting and dyslipidaemia, address wasting first and consider referral to dietician
Patients with BMI430 kg/m2 should be motivated to lose weight. Starvation diets are not recommended in an HIV-infected person (immune
defence mechanisms potentially decreased). Malnutrition has to be addressed where observed. Normal BMI range: 18.5–24.9; Overweight: 25.0–
29.9, Obesity:  30.0 kg/m2
Exercise Promote active lifestyle to prevent obesity, hypertension and diabetes
Emphasize regular moderate-intensity exercise rather than vigorous exercise
Encourage self-directed moderate-level physical activity (take the stairs, bike or walk to work, cycling, swimming, hiking etc.)
Achieve cardiovascular fitness (e.g. 30min brisk walking 5/7 days a week)
Maintain muscular strength and joint flexibility
*Based on recommendations by the US Preventive Services Task Force. Detailed guidelines with evidence grading (full-text) available at
http://odphp.osophs.dhhs.gov/pubs/guidecps/pcpstoc.htm
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Exercise prevents obesity and should include 30min of
brisk walking 5–7 days a week.
Management of dyslipidaemia
Higher LDL-c levels increase the risk of cardiovascular
disease, and reduction thereof reduces this risk; the reverse
is true for high-density lipoprotein (HDL)-cholesterol [6].
Conversely, the cardiovascular disease risk implications of
higher-than-normal levels of triglycerides are less clear, as
is the clinical benefit of treating moderate hypertriglycer-
idaemia.
A healthy diet, exercise and maintaining normal body
weight tend to reduce dyslipidaemia; if not effective,
consider a change of ART and then consider lipid-lowering
medication in high-risk patients (Fig. 1). Co-administration
of statins and ART should be carried out with due
consideration of possible drug–drug interactions (Table 3).
Simvastatin is contraindicated in patients receiving
ritonavir-boosted PI-based ART.
Recommendations for use of the various types of lipid-
lowering medication are indicated in Table 4. Statins and
ezetimibe reduce LDL-cholesterol to a lesser extent; statins
are recommended as first-line therapy to reduce elevated
LDL-cholesterol levels. Only in cases of combined increases
in LDL-cholesterol and triglyceride levels 45mmol/L is it
recommended to initiate therapy aimed at reducing
triglyceride levels; the drug class of choice is the fibrates.
IDV/r
TPV/r 
RTV (full dose)
d4T
LPV/r
fAPV/r 
DRV/r 
ddI
ATV/r 
SQV/r 
ZDV EFV 
3TC / FTC 
ABC
TDF
NVP
PINRTINNRTI
eroMsseL
Metabolic impact of drugs 
Less
More 
Metabolic
impact of 
drugs
Fig. 2 Metabolic impact of individual antiretroviral drugs and drug
classes. 3TC, lamivudine; ABC, abacavir; ATZ, atazanavir; d4T,
stavudine; ddI, didanosine; DRV, darunavir; EFV, efavirenz; FTC,
emtricitabine; IDV, indinavir; LPV, lopinavir; NFV, nelfinavir; NNRTI,
nonnucleoside reverse transcriptase inhibitor; NRTI, nucleos(t)ide
reverse transcriptase inhibitor; NVP, nevirapine; PI, protease
inhibitor; PI/r, protease inhibitor pharmacologically boosted with
ritonavir; RTV, ritonavir (if used as booster,/r); SQV, saquinavir; TDF,
tenofovir DF; TPV, tipranavir; ZDV, zidovudine.
Table 3 Drugs used to manage dyslipidaemia
Drug class Drug Dose Benefit Side effects
Advise on use of statin together with ART
Use with PI/r Use with NNRTI
Statin Atorvastatin 10–80mg qd LDL-c # w Gastrointestinal symptoms, headache,
insomnia, rhabdomyolysis (rare) and
toxic hepatitis
Relative contraindicated Consider higher dose§
Fluvastatin 20–80mg qd LDL-c # * Consider higher dose§ Consider higher dose§
Pravastatin 20–80mg qd LDL-c # * Consider higher dose§, k Consider higher dose§
Rosuvastatin 5–40mg qd LDL-c # w Start with low dosez Start with low dosez
Simvastatin 10–80mg qd LDL-c # Contraindicated Consider higher dose§
Cholesterol uptake # Ezetimibe 10mg qd LDL-c # z Gastrointestinal symptoms
Nicotinic acid
derivative
Acipimox 1.0–1.5 g qd TG # Flushing, rash, headache,
gastrointestinal symptoms
Fibrate Bezafibrate 400mg qd TG # Gastrointestinal symptoms, toxic
hepatitis, myopathy and
rhabdomyolysis
No known drug–drug interactions with ART
Fenofibrate 67–267mg qd TG #
Ciprofibrate 100mg qd TG #
Gemfibrozil 900mg qd/600 bid TG #
Omega 3 acid ester MaxEPA 5 g bid TG #
Omacor 1–2 g bid TG #
Expected range of reductions of LDL-c:
*0.8–1.5mmol/L (35–60mg/dL).
w1.5–2.5mmol/L (60–100 mg/dL).
z0.2–0.5mmol/L (10–20mg/dL).
The ART drug may
§Induce (5 less effect of statin, " dose gradually to achieve expected benefit*,w) or
zInhibit (statin toxicity, # dose) the excretion of the statin.
kException: If used with darunavir, start with lower dose of pravastatin.
LDL-c, LDL-cholesterol; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI/r, protease inhibitors boosted with low dose ritonavir; TG, triglycerides.
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Prevention and management of lipodystrophy
The preferred strategy to prevent lipoatrophy is avoiding
exposure to the two thymidine analogues (stavudine and
zidovudine) [11,12]. Alternatively, pre-emptive switch
away from these drugs should be considered. In cases
where lipoatrophy has developed, reversal is slow and
gradual (Table 5). Other interventions have either not been
sufficiently studied or are known to induce other
complications and are hence not generally recommended.
It is uncertain whether lipohypertrophy can be induced by
specific antiretroviral drugs, and no specific recommenda-
tions on medical prevention strategies can be provided at
this time.
Treatment of type 2 diabetes
Both impaired glucose tolerance (IGT) and impaired fasting
glucose (IFG) (Table 6) increase cardiovascular morbidity
and mortality, and increase the risk of developing diabetes
four to six fold. Patients with IGT and IFG should be
Table 4 Treatment recommendations on management of dyslipidaemia
Type of dyslipidaemia First choice* Combination therapy*
Isolated hypercholesterolaemia [LDL-c 4cut-off (see Table 1)] Statinw 1 Ezetimibe
Combined hyperlipidaemia [(LDL-c >cut-off (see Table 1)
and TG 5–10mmol/Lz]
Statinw 1 Fibrate§ (/nicotinic acid derivative)
Isolated hypertriglyceridaemia (TG 2.3–10mmol/Lz) Diet, alcohol abstinence –
Severe hypertriglyceridaemia (410mmol/Lz) Fibrate 1Omega 3 acid ester (/nicotinic acid derivative)
Isolated low HDL-c (o0.9mmol/L) Fibrate§ 1Nicotinic acid derivative
*Treatment goal is to reduce LDL-c ocut-off levels (see Table 1). Check lipids (fasting) prior to initiation of therapy, 4–12 weeks after initiation or
modification of therapy, and annually once levels are below cut-off levels. Consult with lipid expert if treatment goal can not be reached.
wCheck AST (o  3 ULN) and CK (o  5 ULN) prior to initiation, 4–12 weeks after treatment initiation, and then annually if within normal range.
zIt is not clear whether these levels of elevated TG carry an excess CVD risk; priority should be given to reducing LDL-c to below cut-off levels (see Table 1).
§Combination therapy of statin and gemfibrozil (and less so other fibrates) increases risk of rhabdomyolysis and should be avoided whenever possible.
CVD, cardiovascular disease; HDL-c, HDL-cholesterol; LDL-c, LDL-cholesterol; TG, triglycerides.
Table 5 Prevention and management of lipoatrophy and lipohypertrophy
Lipoatrophy Lipohypertrophy
Prevention
Avoid d4T and ZDV or pre-emptively switch away from them
Management
Modification of ART
 Switch d4 T or AZT to ABC or TDF:
&Only ART modification proven to partially restore subcutaneous fat;
increase in total limb fat  400–500 g/year
&Risk of new toxicity (ABC hypersensitivity reaction?; TDF associated
nephrotoxicity?)
 Switch to regimen not including NRTIs
& Increase in total limb fat  400–500 g/year
&May increase risk of dyslipidaemia
& Less data on virological safety
Surgical intervention
 Offered for cosmetic relief of facial lipoatrophy only (fillers may be
absorbable (limited effect) or permanent (durability of desired cosmetic
effect is unknown)*
 Limited randomized trials and no comparative studies of different
approaches
Pharmacological interventions to treat lipoatrophy have not been proven to
be effective and may introduce new complications
 Pioglitazone – possibly beneficial in patients not taking d4 T
 Rosiglitazone and Pioglitazone – improvement in insulin sensitivity
 Rosiglitazone: increases in blood lipids and possible IHD.
Prevention
No proven strategy
Weight gain expected with effective ART
Weight reduction or avoidance of weight gain may decrease visceral adiposity
Management
Diet and exercise may reduce visceral adiposity;
 Limited data, but possibly reduction of visceral adipose tissue and
improvement in insulin sensitivity and blood lipids, especially in obesity
associated with lipohypertrophy
 No prospective trials in HIV-infected patients to definitely indicate
degree of diet and/or exercise needed to maintain reduction in
visceral fat.
 May worsen subcutaneous lipoatrophy
Pharmacological interventions to treat lipohypertrophy have not been proven
to provide long-term effects and may introduce new complications
 Growth hormone
&Decreases visceral adipose tissue
&May worsen subcutaneous lipoatrophy, may worsen insulin resistance
 Metformin
&Decreases visceral adipose tissue in insulin resistant persons
&May worsen subcutaneous lipoatrophy.
 Surgical therapy can be considered for localised lipomas/buffalo humps
&Duration of effect variable
*See (www.eacs.eu/guide/index.htm) for list of arguments for and against the use of various types of fillers and some examples of specific types.
ABC, abacavir; d4T, stavudine; IHD, ischaemic heart disease; TDF, tenofovir DF; ZDV, zidovudine.
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targeted for lifestyle intervention [body mass index (BMI)
should be reduced in the case of obesity], and their
cardiovascular risk factors should be evaluated and treated
[13,14]. Both type 1 and type 2 diabetes mellitus and the
accompanying metabolic dysregulation may lead to
cardiovascular disease and microangiopathy.
The following treatment goals should be aimed for when
managing patients with type 2 diabetes.
 Glucose control [HbA1co6.5–7.0% without hypogly-
caemia; fasting plasma glucose 4–6mmol/L (73–
110mg/dL)]; normal blood lipids and blood pressure
(see Tables 4 and 10). Preferred antihypertensive drug
class: angiotensin-converting enzyme (ACE) inhibitors.
Table 7 Selected interventions for treatment of diabetes mellitus
Intervention Dose
Expected decrease
in HbA1c (%) Side effects Comments
Lifestyle intervention 1–2 Intra-abdominal and subcutaneous
fat may #
Metformin Start with 500–750mg qd/bid,
increase to maximum tolerated
dose of 2 (–3) g/d in 4–6 weeks
1.5 Gastrointestinal symptoms,
lactic acidosis (rare). Contraindicated
in renal insufficiency.
May worsen lipoatrophy.
Thiazolidinediones Fluid retention, cardiac failure,
weight gain
See also Table 5.
Rosiglitazone 4–8mg/d,
Pioglitazone 15–45mg/d 0.5–1.4
Insulin Refer to text No limit Hypoglycaemia, weight gain. Large doses may be required (1–2 IU/kg).
Table 8 Risk factors for and prevention of hyperlactataemia
Risk factors Prevention/diagnosis Symptoms
Use of d4T4ZDV4ddI
HCV/HBV co-infection
Use of ribavirin
Liver disease
Low CD4 cell count
Pregnancy
Female sex
Obesity
Avoid d4T1 ddI combination
Routine monitoring of serum lactate levels not recommended; does
not predict risk of lactic acidosis
Measurement of serum lactate, bicarbonate and arterial blood
gases1 pH indicated in case of symptoms suggestive of
hyperlactataemia
Close monitoring if other risk factors (see left)
Hyperlactataemia: unexplained nausea, abdominal pain,
hepatomegaly, weight loss
Acidemia: asthenia, dyspnoea, arrhythmias
Guillain–Barre´-like syndrome
d4T, stavudine; ddI, didanosine; ZDV, zidovudine.
Table 6 Diagnostic criteria for diabetes mellitus and its pre-stages*
Fasting plasma
glucose mmol/L
(mg/dL)w
Oral glucose
tolerance test
(OGTT) 2-h value
mM (mg/dL)z
Diabetes  7.0 (126) OR - - !  11.1 (200)
Impaired glucose
tolerance (IGT)
o 7.0 (126) AND - - ! 7.8–11.0 (140–199)
Impaired fasting
glucose (IFG)
6.1–6.9 (110–125) AND- - ! o 7.8 (140)
*As defined by WHO and International Diabetes Federation (2005).
wAn abnormal finding should be repeated before confirming the diagnosis.
zIs recommended in patients with fasting blood glucose 6.1–6.9mmol/L
(110–125mg/dL) as it may diagnose patients with overt diabetes.
Both IGT and IFG increase CV morbidity and mortality, and increase the risk of
developing diabetes by four to six fold. These patients should be targeted for
lifestyle intervention, and their CV risk factors must be evaluated and treated.
Table 9 Management of hyperlactataemia
Serum lactate
(mmol/L) Symptoms Action
45* Yes/no Repeat test under standardized conditions to confirm & obtain arterial pH and bicarbonate*
If confirmed, exclude other obvious causes
Arterial pH # and/or bicarbonate # *: stop NRTIs
Arterial pH and/or bicarbonate normal: Consider switch from high to low risk NRTI & monitor carefully OR stop NRTIs
2–5 Yes Exclude other causes; if none found: watchfully follow up OR consider switch from high to low risk NRTI OR stop NRTI
2–5 No Repeat test
if confirmed: watchfully follow up
o2 None
*Lactic acidosis is a rare but life-threatening situation usually associated with symptoms; high risk if serum lactate 45 and especially 410mmol/L.
NRTI, nucleos(t)ide reverse transcriptase inhibitor.
78 JD Lundgren et al.
r 2008 British HIV Association HIV Medicine (2008) 9, 72–81
Ta
bl
e
10
M
an
ag
em
en
t
ba
se
d
on
bl
oo
d
pr
es
su
re
m
ea
su
re
m
en
ts
an
d
th
e
di
ag
no
si
s
of
hy
pe
rt
en
si
on
O
th
er
ri
sk
fa
ct
or
s
an
d
di
se
as
e
hi
st
or
y
B
lo
od
pr
es
su
re
(m
m
H
g)
*
–
le
ve
ls
1
di
ag
no
si
s
&
gr
ad
in
g
of
hy
pe
rt
en
si
on
N
or
m
al
:
SB
P
1
2
0
–
1
2
9
or
D
B
P
8
0
–
8
4
H
ig
h
no
rm
al
:
SB
P
1
3
0
–
1
3
9
or
D
B
P
8
5
–
8
9
G
ra
de
1
:
SB
P
1
4
0
–
1
5
9
or
D
B
P
9
0
–
9
9
G
ra
de
2
:
SB
P
1
6
0
–
1
7
9
or
D
B
P
10
0
–
10
9
G
ra
de
3
:
SB
P

1
8
0
or
D
B
P

11
0
N
o
ot
he
r
ri
sk
fa
ct
or
s
A
ve
ra
ge
ri
sk
N
o
B
P
in
te
rv
en
ti
on
A
ve
ra
ge
ri
sk
N
o
B
P
in
te
rv
en
ti
on
Lo
w
ad
de
d
ri
sk
Li
fe
st
yl
e
ch
an
ge
s
fo
r
se
ve
ra
l
m
on
th
sw
,
th
en
po
ss
ib
le
dr
ug
th
er
ap
yz
M
od
er
at
e
ad
de
d
ri
sk
Li
fe
st
yl
e
ch
an
ge
s
fo
r
se
ve
ra
l
m
on
th
sw
,
th
en
dr
ug
th
er
ap
yz
H
ig
h
ad
de
d
ri
sk
Im
m
ed
ia
te
dr
ug
th
er
ap
yz
an
d
lif
es
ty
le
ch
an
ge
sw
1–
2
ri
sk
fa
ct
or
s§
Lo
w
ad
de
d
ri
sk
Li
fe
st
yl
e
ch
an
ge
sw
Lo
w
ad
de
d
ri
sk
Li
fe
st
yl
e
ch
an
ge
sw
M
od
er
at
e
ad
de
d
ri
sk
Li
fe
st
yl
e
ch
an
ge
s
fo
r
se
ve
ra
l
m
on
th
sw
,
th
en
dr
ug
th
er
ap
yz
M
od
er
at
e
ad
de
d
ri
sk
Li
fe
st
yl
e
ch
an
ge
s
fo
r
se
ve
ra
l
m
on
th
sw
,
th
en
dr
ug
th
er
ap
yz
Ve
ry
hi
gh
ad
de
d
ri
sk
Im
m
ed
ia
te
dr
ug
th
er
ap
yz
an
d
lif
es
ty
le
ch
an
ge
sw
3
or
m
or
e
ri
sk
fa
ct
or
s§
or
ta
rg
et
or
ga
n
di
se
as
ez
or
di
ab
et
es
M
od
er
at
e
ad
de
d
ri
sk
Li
fe
st
yl
e
ch
an
ge
sw
H
ig
h
ad
de
d
ri
sk
D
ru
g
th
er
ap
yz
an
d
lif
es
ty
le
ch
an
ge
sw
H
ig
h
ad
de
d
ri
sk
D
ru
g
th
er
ap
yz
an
d
lif
es
ty
le
ch
an
ge
sw
H
ig
h
ad
de
d
ri
sk
D
ru
g
th
er
ap
yz
an
d
lif
es
ty
le
ch
an
ge
sw
Ve
ry
hi
gh
ad
de
d
ri
sk
Im
m
ed
ia
te
dr
ug
th
er
ap
yz
an
d
lif
es
ty
le
ch
an
ge
sw
A
ss
oc
ia
te
d
cl
in
ic
al
co
nd
it
io
ns
k
H
ig
h
ad
de
d
ri
sk
D
ru
g
th
er
ap
yz
an
d
lif
es
ty
le
ch
an
ge
sw
Ve
ry
hi
gh
ad
de
d
ri
sk
Im
m
ed
ia
te
dr
ug
th
er
ap
yz
an
d
lif
es
ty
le
ch
an
ge
sw
Ve
ry
hi
gh
ad
de
d
ri
sk
Im
m
ed
ia
te
dr
ug
th
er
ap
yz
an
d
lif
es
ty
le
ch
an
ge
sw
Ve
ry
hi
gh
ad
de
d
ri
sk
Im
m
ed
ia
te
dr
ug
th
er
ap
yz
an
d
lif
es
ty
le
ch
an
ge
sw
Ve
ry
hi
gh
ad
de
d
ri
sk
Im
m
ed
ia
te
dr
ug
th
er
ap
yz
an
d
lif
es
ty
le
ch
an
ge
sw
* D
B
P
5
di
as
to
lic
bl
oo
d
pr
es
su
re
;
SB
P
5
sy
st
ol
ic
bl
oo
d
pr
es
su
re
.
R
ep
ea
te
d
bl
oo
d
pr
es
su
re
m
ea
su
re
m
en
ts
sh
ou
ld
be
us
ed
fo
r
st
ra
ti
fi
ca
ti
on
.
w R
ec
om
m
en
de
d
lif
es
ty
le
in
te
rv
en
ti
on
s,
se
e
Ta
bl
e
2.
Ta
bl
e
ad
ap
te
d
fr
om
J.
H
yp
er
te
ns
io
n
20
03
;
21
:
17
79
–1
78
6.
z D
ru
g
th
er
ap
y
ca
n
be
in
it
ia
te
d
ei
th
er
w
it
h
a
lo
w
do
se
of
a
si
ng
le
ag
en
t
or
w
it
h
a
lo
w
do
se
co
m
bi
na
ti
on
of
tw
o
ag
en
ts
.T
o
re
ac
h
ta
rg
et
bl
oo
d
pr
es
su
re
,a
pr
op
or
ti
on
of
pa
ti
en
ts
w
ill
re
qu
ir
e
co
m
bi
na
ti
on
th
er
ap
y.
Fo
r
in
di
ca
ti
on
s
an
d
co
nt
ra
in
di
ca
ti
on
s
fo
r
th
e
m
aj
or
cl
as
se
s
of
an
ti
hy
pe
rt
en
si
ve
dr
ug
s
se
e
(w
w
w
.e
ac
s.
eu
/g
ui
de
/in
de
x.
ht
m
).
M
ed
ic
al
tr
ea
tm
en
t
of
un
co
m
pl
ic
at
ed
hy
pe
rt
en
si
on
:fi
rs
t
ch
oi
ce
:T
hi
az
id
e
or
A
C
E-
in
hi
bi
to
r,
se
co
nd
ch
oi
ce
:A
m
lo
di
pi
ne
(s
ta
rt
w
it
h
5
m
g
qd
)o
r
co
m
bi
na
ti
on
of
tw
o
an
ti
hy
pe
rt
en
si
ve
s.
A
w
ai
t
(2
–)
6
w
ee
ks
of
th
er
ap
y
to
as
se
ss
lo
w
er
in
g
of
th
e
bl
oo
d
pr
es
su
re
.
G
ra
de
3
hy
pe
rt
en
si
on
or
la
ck
of
ac
hi
ev
em
en
t
of
go
al
(s
ee
be
lo
w
)
2–
6
w
ee
ks
af
te
r
co
m
m
en
ci
ng
se
co
nd
ch
oi
ce
:
co
ns
ul
t
hy
pe
rt
en
si
on
ex
pe
rt
.
C
oa
dm
in
is
tr
at
io
n
of
PI
s
an
d
ca
lc
iu
m
ch
an
ne
lb
lo
ck
er
s
(C
C
B
)
m
ay
re
su
lt
in
si
gn
ifi
ca
nt
ly
in
cr
ea
se
d
C
C
B
-p
la
sm
a
co
nc
en
tr
at
io
ns
re
su
lt
in
g
in
in
cr
ea
se
d
ri
sk
of
to
xi
ci
ty
an
d
pr
ol
on
ge
d
ef
fe
ct
;
N
N
R
TI
s
m
ay
de
cr
ea
se
pl
as
m
a
co
nc
en
tr
at
io
ns
of
C
C
B
s
an
d
re
du
ce
ef
fi
ca
cy
of
C
C
B
.A
te
no
lo
l
is
th
e
pr
ef
er
re
d
b-
bl
oc
ke
r
w
he
n
co
m
bi
ne
d
w
it
h
A
R
Vs
;
m
et
op
ro
lo
l
pl
as
m
a
co
nc
en
tr
at
io
ns
m
ay
be
in
cr
ea
se
d
by
bo
os
te
d
PI
s.
C
on
su
lt
a
cl
in
ic
al
ph
ar
m
ac
ol
og
is
t
or
ph
ar
m
ac
is
t
w
he
n
co
m
bi
ni
ng
an
ot
he
r
an
ti
hy
pe
rt
en
si
ve
ag
en
t
w
it
h
A
R
Vs
.
§ R
is
k
fa
ct
or
s
in
cl
ud
e
ag
e
(4
45
ye
ar
s
fo
r
m
en
;
4
55
ye
ar
s
fo
r
w
om
en
),
sm
ok
in
g,
fa
m
ily
hi
st
or
y
of
pr
em
at
ur
e
C
VD
.
z
A
ss
oc
ia
te
d
cl
in
ic
al
co
nd
it
io
ns
(C
VD
,
C
H
D
,
re
na
l
di
se
as
e,
pe
ri
ph
er
al
va
sc
ul
ar
di
se
as
e,
ad
va
nc
ed
re
ti
no
pa
th
y)
.
k T
ar
ge
t
or
ga
n
da
m
ag
e
(le
ft
ve
nt
ri
cu
la
r
hy
pe
rt
ro
ph
y,
ul
tr
as
ou
nd
ev
id
en
ce
of
ar
te
ri
al
w
al
l
th
ic
ke
ni
ng
,
m
ic
ro
al
bu
m
in
ur
ia
).
G
oa
ls
of
tr
ea
tm
en
t:
R
ed
uc
ed
SB
P
to
o
14
0/
90
m
m
H
g
an
d
to
lo
w
er
va
lu
es
if
to
le
ra
te
d,
w
it
h
di
ab
et
es
SB
Po
13
0/
80
m
m
H
g;
SB
P
va
lu
es
o
14
0
m
m
H
g
m
ay
be
di
ffi
cu
lt
to
ac
hi
ev
e
in
th
e
el
de
rl
y.
W
ar
ni
ng
:
C
au
ti
on
re
ga
rd
in
g
dr
ug
–d
ru
g
in
te
ra
ct
io
ns
w
it
h
an
ti
hy
pe
rt
en
si
ve
dr
ug
s
an
d
A
R
T.
EACS guidelines on the prevention and management of metabolic diseases in HIV 79
r 2008 British HIV Association HIV Medicine (2008) 9, 72–81
 Acetylsalicylic acid (75–150mg/d) should be considered
in all patients.
 Nephropathy and retinopathy screening should be
performed as in diabetic patients without HIV infection.
 Consultation with a specialist in diabetology is recom-
mended.
There are several tested interventions available to obtain
glucose control in type 2 diabetes (Table 7). These
interventions should be individualized as follows.
 Metformin for an overweight patient.
 Pioglitazone (rosiglitazone) for a lipoatrophic patient.
 Metformin and glitazones can be combined.
 Diabetes is typically a progressive disease and medica-
tion must be modified accordingly.
 There are currently no data on the use of other oral
antidiabetic drugs (sulfonylureas, glinides, exenatide,
sitagliptin and a-glucosidase inhibitors) in the treat-
ment of HIV-infected patients taking ART.
 If treatment targets cannot be reached with oral agents,
insulin should be started. Start with 10 IU of long-acting
insulin at bedtime. Teach the patient to self-monitor
fasting glucose values and increase the dose by 2 units
every 3 days until fasting plasma glucose o6.1mmol/L
is achieved.
 Oral metformin should be continued with insulin
therapy.
Prevention and management of hyperlactataemia
There are multiple risk factors for hyperlactataemia in HIV-
infected populations [15], and the symptoms associated
with this condition are diverse (Table 8). To reduce the risk
of hyperlactataemia it is important to avoid the combina-
tion of certain antiretroviral and anti-hepatitis drugs
(stavudine, didanosine and ribavirin). Of note, routine
measurements of S-lactate to screen for hyperlactataemia
are not recommended.
Table 9 depicts the recommended approach for patients
for whom an S-lactate measurement has been taken based
on a suspicion that the patient may suffer from hyperlac-
tataemia.
Metabolic acidosis associated with increased S-lactate
levels (lactic acidosis) is a life-threatening condition. The
metabolic acidosis is diagnosed on arterial puncture. For
such patients it is recommended to:
 admit the patient;
 stop all ART;
 provide intravenous fluid support;
Perhaps use vitamin supplementation [vitamin B complex
forte 4mL twice a day (bid); riboflavin 20mg bid; thiamine
100mg bid; L-carnitine 1000mg bid], although the benefit
is not well documented.
Management based on blood pressure measurement
and/or diagnosis of hypertension
The intensity of interventions applied to treat elevated
blood pressure varies depending on the measured blood
pressure (caution: white-coat hypertension) and on the
number of risk factors for various diseases associated with
hypertension. The higher the blood pressure and the more
risk factors, the more aggressive the approach needs to be
(Table 10) [16].
The two principal interventions are lifestyle modification
(especially reduction of BMI in the case of obesity) and use
of antihypertensives. The footnote to Table 10 describes the
recommended approach to the use of antihypertensives. Of
note, there is the potential for drug–drug interactions
between calcium-channel blockers and ART.
The goal of the interventions is to reduce systolic blood
pressure to o140/90mmHg and to lower values if
tolerated. For patients with diabetes mellitus, the target
systolic blood pressure is o130/80mmHg. Of note, in the
elderly, it may be difficult to achieve these goals.
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